View in EDS

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.

Saved in:
Bibliographic Details
Title: Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Authors: Rannikko JH; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland; Turku Doctoral Program of Molecular Medicine, University of Turku, Turku, Finland., Verlingue L; Institut Gustave Roussy, Paris and Centre Leon Berard in Lyon, Lyon, France., de Miguel M; START-CIOCC HM Sanchinarro, Madrid, Spain., Pasanen A; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Robbrecht D; Erasmus Medical Center/Cancer Institute, Rotterdam, the Netherlands., Skytta T; Tampere University Hospital, Tampere, Finland., Iivanainen S; Oulu University Hospital, University of Oulu, Oulu, Finland., Shetty S; University of Birmingham/University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Ma YT; University of Birmingham/University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Graham DM; The Christie NHS Foundation Trust, Manchester, UK., Arora SP; Mays Cancer Center, UT Health San Antonio, San Antonio, TX, USA., Jaakkola P; Department of Oncology, Turku University Hospital and University of Turku, Turku, Finland., Yap C; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Xiang Y; INDIVIDRUG Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Mandelin J; Faron Pharmaceuticals Ltd, Turku, Finland., Karvonen MK; Faron Pharmaceuticals Ltd, Turku, Finland., Jalkanen J; Faron Pharmaceuticals Ltd, Turku, Finland., Karaman S; INDIVIDRUG Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Wihuri Research Institute, Helsinki, Finland., Koivunen JP; Oulu University Hospital, University of Oulu, Oulu, Finland; Faron Pharmaceuticals Ltd, Turku, Finland., Minchom A; Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK., Hollmén M; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland; Faron Pharmaceuticals Ltd, Turku, Finland. Electronic address: maijal@utu.fi., Bono P; Terveystalo Finland and University of Helsinki, Helsinki, Finland. Electronic address: petri.bono@terveystalo.com.
Source: Cell reports. Medicine [Cell Rep Med] 2023 Dec 19; Vol. 4 (12), pp. 101307. Date of Electronic Publication: 2023 Dec 05.
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3791
DOI:10.1016/j.xcrm.2023.101307